Findings from a recent study demonstrate that comprehensive genetic profiling (CGP) is a useful tool in directing patient care, including the identification of targeted therapies and enrollment in clinical trials.
Kimberly Rohan, nurse practitioner at the Edward Cancer Center in Naperville, Illinois, presented these findings today at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada.
A retrospective analysis was performed on the results of CGP collected from 46 patients with a cancer diagnosis utilising Foundation Medicine’s FoundationOne® technology over a three-year period.
Each case was reviewed for number of genomic alterations identified, treatment associated with potential for clinical trial benefit, therapies associated with lack of response and clinical decisions made due to the CGP findings.
Two hundred and sixty-three genomic alterations were identified in this patient population.
Of these patients, 13 percent were referred to clinical trials and 26 percent resulted in a change of therapy.
Among those diagnosed with lung cancer, six percent were referred to clinical trials and 34 percent resulted in a change of therapy.
“We’re thrilled to have achieved our goal, analyzing how information obtained in genomic profiling can impact or change patient care,” said Rohan.
“Our findings, ranging from six to 13 percent of patients referred to clinical trials, exceeds the national clinical trial enrollment and highlights a substantial opportunity for patients undergoing cancer treatment.”